This review outlines a clinical management approach for patients with HF-PEF following the neutral results of the TOPCAT trial.
May guide HFpEF management after TOPCAT; leaves open identification of effective therapies.
Although patients with heart failure and preserved ejection fraction (HF-PEF) represent nearly half of the population with chronic heart failure, few evidence-based medical therapies are available. The neutral overall results of the TOPCAT trial of spironolactone in HF-PEF leave clinicians who treat heart failure with an ongoing clinical dilemma. In this review, we outline an approach to the clinical management of the patient with HF-PEF synthesizing data from available clinical trials and expert consensus.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: